摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 2-(trifluoromethyl)furan-3-carboxylate | 23584-63-6

中文名称
——
中文别名
——
英文名称
ethyl 2-(trifluoromethyl)furan-3-carboxylate
英文别名
ethyl 3-trifluoromethyl-2-furancarboxylate;2-trifluoromethylfuran-3-carboxylic acid ethyl ester;ethyl 2-trifluoromethyl-furan-3-carboxylate;ethyl 2-trifluoromethyl-3-furancarboxylate
ethyl 2-(trifluoromethyl)furan-3-carboxylate化学式
CAS
23584-63-6
化学式
C8H7F3O3
mdl
——
分子量
208.137
InChiKey
VETYPAIUONGOHC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    226.4±40.0 °C(Predicted)
  • 密度:
    1.299±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    39.4
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    ethyl 2-(trifluoromethyl)furan-3-carboxylate 、 lithium hydroxide 作用下, 以 四氢呋喃 为溶剂, 反应 12.0h, 生成 2-(三氟甲基)呋喃-3-羧酸
    参考文献:
    名称:
    [EN] PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY
    [FR] INHIBITEURS DE L'ACTIVITÉ D'IRAK4 À BASE DE PYRAZOLOPYRIMIDINE
    摘要:
    本发明涉及式(I)的IRAK4的吡唑吡咯啉抑制剂,并提供包含这种抑制剂的组合物,以及用于治疗IRAK4介导或相关疾病或病症的方法。
    公开号:
    WO2016144846A1
  • 作为产物:
    描述:
    ethyl 2-diazo-3-oxo-4,4,4-trifluorobutyrate 在 Ph2(OAc)4 硫酸 作用下, 以 四氯化碳 为溶剂, 反应 2.33h, 生成 ethyl 2-(trifluoromethyl)furan-3-carboxylate
    参考文献:
    名称:
    A simple synthesis of fluoroalkyl substituted dihydrofurans by rhodium(II)-catalyzed 1,3-dipolar reactions
    摘要:
    The rhodium(II)-catalyzed reactions of ethyl 2-diazo-fluoroalkylacetoacetate 1 with vinyl ethers have been studied. The reactions of 1a-e with isobutyl vinyl ethers afforded dihydrofuroates 3a-e in good to excellent yields. Further transformation of the dihydrofuroates by acid-catalyzed alcohol elimination could give alpha -fluoroalkyl-beta -furoates readily. Similarly, stable diazo compounds 1a and b reacted with cyclic vinyl ethers to give 1,3-dipolar cycloaddition products. Interestingly, only vinyl C-H insertion compound was obtained concerning the reaction of la with 2,5-dimethylfuran. The reaction mechanism was also discussed. (C) 2001 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0040-4020(01)00183-1
点击查看最新优质反应信息

文献信息

  • Pyrimidine derivatives as IL-8 receptor antagonists
    申请人:——
    公开号:US20040087601A1
    公开(公告)日:2004-05-06
    Compounds containing the pyrimidine nucleus and their use to treat diseases and conditions related to inappropriate Interleukin-8 receptor activity are disclosed. The compounds are of the formula I 1 In these compounds, Q is preferably unsubstituted and substituted heterocyclyl; U is usually hydrogen or fluorine; and V is preferably hydrogen, halogen, alkyl, —O—alkyl or —S-alkyl. A representative example is: 2
    含有嘧啶核的化合物及其用于治疗与不适当的白细胞介素-8受体活性相关的疾病和症状的用途已被披露。这些化合物的结构式为I 1 在这些化合物中,Q最好是未取代或取代的杂环烷基;U通常是氢或氟;V最好是氢、卤素、烷基、—O—烷基或—S-烷基。一个代表性的例子是: 2
  • [EN] (2S)-2-((PYRIMIDIN-4-YL)AMINO)-4-METHYLPENTANOIC ACID AMINOETHYLAMID DERIVATIVES AS IL-8 RECEPTOR MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS<br/>[FR] DERIVES D'AMINOETHYLAMIDE D'ACIDE (2S)-2-((PYRIMIDIN-4-YL)AMINO)-4-METHYLPENTANOIQUE UTILISES COMME MODULATEURS DU RECEPTEUR DE L'IL-8 POUR TRAITER L'ATHEROSCLEROSE ET LA POLYARTHRITE RHUMATOIDE
    申请人:PHARMACOPEIA DRUG DISCOVERY
    公开号:WO2004069829A1
    公开(公告)日:2004-08-19
    The invention relates to compounds of the formula: (I); wherein R1 is a basic moiety having the structure -NH(CH2)2NR5R6, (Formula II) or (Formula II); wherein R5, R6 and R7 are independently selected from H, (1-6C)alkyl, (2-6C)alkenyl; (3-8C)cycloalkyl, and (1-6C)alkyl substituted with furanyl, (1-6C)alkoxy, (3-8C)cycloalkyl, trifluoromethyl or amido; or R5 and R6 together with N to which they are attached are a (4-8) membered heterocycle, which heterocycle may be substituted with (1-6C)alkoxy, trifluoromethyl or amido and which heterocycle may be fused with another (5-6) membered heterocycle; n is 1, 2 or 3; and the ring structure A represents a (4-6) membered heterocycle; R2 is (1-6C)alkyl, optionally substituted with (1-6C)alkoxy; R3 is aryl, heterocyclyl, -X-(CH2)maryl or -X-(CH2)m-heterocyclyl, wherein X is O, S or NR8, R8 being H or (1-6C)alkyl, and m is 0, 1, 2 or 3; and R4 is H, (1-8C)akyl, (1-8C)alkoxy or (2-8C)alkenyl, the alkyl moiety of each optionally being substituted with hydroxy, halogen, cyano, nitro, oxo, amino, alkylamino, dialkylamino, amido, alkylamido, carboxy, (1-8C)alkoxy, (1-8C)alkylthio, perfluoro (1-4C)alkyl, (3-8C)cycloalky, aryl, aryloxy, heterocyclyl or-0-heterocyclyl; or a pharmaceutically acceptable salt thereof. The compounds of the invention are Il-8 receptor modulators, in particular inhibitors thereof, and can be used for treating or preventing Il-8 receptor mediated disorders, such as atherosclerosis, inflammation, rheumatoid arthritis and related disorders.
    该发明涉及以下式的化合物:(I);其中R1是具有结构-NH(CH2)2NR5R6的碱性基团,(式II)或(式II);其中R5、R6和R7分别选自H、(1-6C)烷基、(2-6C)烯基;(3-8C)环烷基,以及用呋喃基、(1-6C)烷氧基、(3-8C)环烷基、三氟甲基或酰胺取代的(1-6C)烷基;或者R5和R6与它们连接的N一起是(4-8)成员杂环,该杂环可以用(1-6C)烷氧基、三氟甲基或酰胺取代,并且该杂环可以与另一个(5-6)成员杂环融合;n为1、2或3;环结构A代表(4-6)成员杂环;R2是(1-6C)烷基,可选地取代(1-6C)烷氧基;R3是芳基、杂环基、-X-(CH2)芳基或-X-(CH2)m-杂环基,其中X为O、S或NR8,R8为H或(1-6C)烷基,m为0、1、2或3;R4为H、(1-8C)烷基、(1-8C)烷氧基或(2-8C)烯基,每个烷基基团可选地取代羟基、卤素、氰基、硝基、氧代、氨基、烷基氨基、二烷基氨基、酰胺、烷基酰胺、羧基、(1-8C)烷氧基、(1-8C)烷基硫氧基、全氟(1-4C)烷基、(3-8C)环烷基、芳基、芳氧基、杂环基或-0-杂环基;或其药学上可接受的盐。该发明的化合物是Il-8受体调节剂,特别是其抑制剂,并可用于治疗或预防Il-8受体介导的疾病,如动脉粥样硬化、炎症、类风湿关节炎及相关疾病。
  • [EN] EP4 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES AUX RECEPTEURS EP4
    申请人:PHARMAGENE LAB LTD
    公开号:WO2004067524A1
    公开(公告)日:2004-08-12
    Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either -(CH2)n-X-, where n is 1 or 2 and X is O, S, S(=O), S(=O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is -C(=O)NRN2-, where RN2 is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R3 is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R5 is either:(i) carboxy;(ii) a group of formula (II); or(iii) a group of formula (III):, wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl;(iv) tetrazol-5-yl.
    式(I)的化合物:其中:R2为H或可选择地取代的C1-4烷基基团;Y为-(CH2)n-X-,其中n为1或2,X为O、S、S(=O)、S(=O)2或NRN1,其中RN1从H或可选择地取代的C1-4烷基中选择,或Y为-C(=O)NRN2-,其中RN2从H、可选择地取代的C1-7烷基或C5-20芳基中选择;R3为可选择地取代的C6芳基基团,连接到另一个可选择地取代的C6芳基基团,如果两个C6芳基基团均为苯环,则两个环之间可能有氧桥,在两个环上的连接处相邻结合;A为单键或C1-3烷基基团;R5为以下之一:(i)羧基;(ii)式(II)的基团;或(iii)式(III)的基团:其中R为可选择地取代的C1-7烷基、C5-20芳基或NRN3RN4,其中RN3和RN4独立地从可选择地取代的C1-4烷基中选择;(iv)四唑-5-基。
  • EP4 receptor antagonists
    申请人:——
    公开号:US20040192767A1
    公开(公告)日:2004-09-30
    Compounds of formula (I): 1 wherein: R 2 is H or an optionally substituted C 1-4 alkyl group; Y is either —(CH 2 ) n —X—, where n is 1 or 2 and X is O, S, S(═O), S(═O) 2 , or NR N1 , where R N1 is selected from H or optionally substituted C 1-4 alkyl, or Y is —C(═O)NR N2 —, where R N2 is selected from H, and optionally substituted C 1-7 alkyl or C 5-20 aryl; R 3 is an optionally substituted C 6 aryl group linked to a further optionally substituted C 6 aryl group, wherein if both C 6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C 1-3 alkylene group; and R 5 is either: (i) carboxy; (ii) a group of formula (II): 2 or (iii) a group of formula (III): 3 wherein R is optionally substituted C 1-7 alkyl, C 5-20 aryl or NR N3 R N4 , where R N3 and R N4 are independently selected from optionally substituted C 1-4 alkyl; (iv) tetrazol-5-yl.
    化学式为(I)的化合物:其中:R2为H或可选取代的C1-4烷基;Y为—(CH2)n—X—,其中n为1或2,X为O,S,S(═O),S(═O)2,或NRN1,其中RN1选择自H或可选取代的C1-4烷基,或者Y为—C(═O)NRN2—,其中RN2选择自H,可选取代的C1-7烷基或C5-20芳基;R3为可选取代的C6芳基,连接到另一个可选取代的C6芳基,如果两个C6芳基均为苯环,则两个环之间可能有一个氧桥,在两个环上相邻的链接处结合;A为单键或C1-3烷基;R5为:(i)羧基;(ii)化学式为(II)的基团:(iii)化学式为(III)的基团:其中R为可选取代的C1-7烷基,C5-20芳基或NRN3RN4,其中RN3和RN4独立选择自可选取代的C1-4烷基;(iv)四唑-5-基。
  • Pyrethroid esters
    申请人:Roussel-Uclaf
    公开号:US05405865A1
    公开(公告)日:1995-04-11
    A compound in all possible stereoisomeric forms and mixtures thereof of the formula ##STR1## wherein the substituents are defined as in the specification having pesticidal properties.
    一种具有杀虫性能的化合物,其具有所有可能的立体异构体形式和它们的混合物,化学式为##STR1##其中取代基的定义如规范中所述。
查看更多

同类化合物

除草醚 醋糠硫胺 醋呋三嗪 酪氨酰-甘氨酰-色氨酰-蛋氨酰-门冬氨酰-苯基丙氨酰-甘氨酸 糠酸(呋喃甲酸) 糠酸異戊酯 糠酸烯丙酯 碘化溴刚 硫代糠酸甲酯 硝基呋喃杂质 硝呋隆 硝呋醛肟标准品 硝呋美隆 硝呋维啶 硝呋立宗 硝呋甲醚 硝呋烯腙盐酸盐 硝呋烯腙 硝呋替莫 硝呋拉定 硝呋太尔杂质B 硝呋噻唑 硝呋乙宗 盐酸呋喃它酮 盐酸呋喃他酮 甲基7-[5-乙酰氨基-4-[(2-溴-4,6-二硝基苯基)偶氮]-2-甲氧苯基]-3-羰基-2,4,10-三氧杂-7-氮杂十一烷-11-酸酯 甲基5-溴-3-甲基-2-糠酸酯 甲基5-乙酰氨基-2-糠酸酯 甲基5-{[(氯乙酰基)氨基]甲基}-2-糠酸酯 甲基5-(甲氧基甲基)-2-甲基呋喃-3-羧酸酯 甲基5-(溴甲基)-4-(氯甲基)-2-糠酸酯 甲基5-(乙氧基甲基)-2-甲基-3-糠酸酯 甲基5-({[5-(三氟甲基)-2-吡啶基]硫代}甲基)-2-糠酸 甲基5-(4-甲酰基苯基)-2-糠酸酯 甲基5-(3-甲酰基苯基)-2-糠酸酯 甲基4-甲基-3-糠酸酯 甲基4-溴-5-甲基-2-糠酸酯 甲基4-乙酰基-5-甲基-2-糠酸酯 甲基4,6-二氯-3-(二乙基氨基)呋喃并[3,4-c]吡啶-1-羧酸酯 甲基3-羟基呋喃并[3,2-b]吡啶-2-羧酸酯 甲基3-甲酰基-2-糠酸酯 甲基3-氨基呋喃并[2,3-b]吡啶-2-羧酸酯 甲基3-氨基-5-(2-甲基-2-丙基)-2-糠酸酯 甲基3-乙基-4-苯基-2-糠酸酯 甲基3-(叔丁氧基羰基)呋喃-2-羧酸甲酯 甲基2-甲氧基-5-苯基-3-糠酸酯 甲基2-乙基-3-糠酸酯 甲基(2Z)-2-呋喃-2-基-3-(5-硝基呋喃-2-基)丙-2-烯酸酯 甲基(2E)-3-[5-(氯甲酰基)-2-呋喃基]丙烯酸酯 环己基呋喃-2-羧酸酯